Lucid Diagnostics (LUCD) AI Stock Analysis

• Market Cap: $134.83M
• Dividend Yield: N/A
• Average Volume (3M): 1.23M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: 79.00%
• EPS Growth: 15.03%
• Country: US
• Employees: 72
• Sector: Healthcare
• Sector Strength: 64
• Industry: Medical - Devices
• EPS (TTM): -1.07
• Shares Outstanding: 105,333,694
• 10 Day Avg. Volume: 2,014,044
• 30 Day Avg. Volume: 1,227,555
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 28.19
• Price to Cash Flow (P/CF): -2.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3.75
• Price Target Upside: 192.97% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

Lucid Diagnostics' overall stock score reflects a mixed outlook. The company demonstrates strong technical performance and has fortified its financial position through recent capital raises, which supports potential growth. However, significant financial challenges remain, with ongoing struggles in profitability and cash flow stability due to negative margins and high reliance on debt. Despite a positive earnings call sentiment and technical trend, the valuation metrics highlight underlying risks.

Positive Factors

Earnings and Revenue Growth

Lucid Diagnostics turned in a solid Q4 volume beat, and for 2024, turned in +79% Y/Y revenue growth, driven by +41% and +32% Y/Y growth in volumes and ASPs, respectively.

Insurance Coverage

Lucid obtained positive commercial insurance coverage for EsoGuard from Highmark Blue Cross Blue Shield (BSBS) of NY.

Regulatory Approvals

The company has reached a milestone in its regulatory pathway by submitting its clinical data package for Medicare coverage, which is expected to significantly increase adoption.

Negative Factors

Operating Expenses

LUCD's operating expenses were modestly above the analyst's estimate.

Reimbursement Criteria

No current test has yet achieved the criteria for reimbursement eligibility, including analytic validity, clinical validity, and clinical utility data.

Revenue Challenges

LUCD missed consensus revenue despite having grown test volume significantly as collections lagged test volume.

Lucid Diagnostics Business Overview & Revenue Model

Company Description

Lucid Diagnostics (LUCD) is a medical technology company operating in the healthcare sector, with a focus on the early detection of esophageal precancer and cancer. The company's core product is the EsoGuard diagnostic test, which is designed to detect Barrett's Esophagus, a condition that can lead to esophageal cancer. Lucid Diagnostics aims to provide innovative solutions for gastroenterologists and patients to improve early diagnosis and treatment outcomes.

How the Company Makes Money

Lucid Diagnostics makes money primarily through the commercialization of its EsoGuard diagnostic test. The company's revenue model is based on the sale and use of this test by healthcare providers and laboratories. Lucid Diagnostics generates revenue by offering EsoGuard as a service to detect esophageal precancer and cancer, billing insurance companies and healthcare providers for its usage. The company's earnings are also influenced by its strategic partnerships with laboratories and healthcare networks that facilitate the distribution and adoption of the EsoGuard test. Additionally, Lucid Diagnostics may engage in research collaborations and licensing agreements that contribute to its revenue stream.

Lucid Diagnostics Financial Statement Overview

Summary

Lucid Diagnostics is experiencing rapid revenue growth but is struggling with profitability, cash flow, and leverage. The company faces high operating losses and negative cash flows, indicating significant financial instability. While there are some improvements in equity, substantial risks remain due to reliance on debt and negative margins.

Income Statement

Lucid Diagnostics has shown significant revenue growth from 2023 to 2024 with a revenue growth rate of 178883%. However, the company is still experiencing negative gross profit and net income, leading to negative margins. The net profit margin and EBIT margin are severely negative, indicating substantial losses relative to revenue. The financials reflect a challenging profitability position.

Balance Sheet

The company's debt-to-equity ratio has seen improvement due to rising stockholders' equity but remains concerning. The equity ratio is low, indicating heavy reliance on liabilities. The company's assets are largely financed through debt and liabilities, posing a risk amidst negative equity in previous years. However, the current positive equity marks a potential recovery trajectory.

Cash Flow

Lucid Diagnostics has a negative free cash flow, indicating significant cash outflow. The operating cash flow to net income ratio is negative, reflecting operational challenges. The company heavily relies on financing activities to manage cash flow, which is unsustainable in the long term. Improvement in cash generation from operations is crucial.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
4.35B	2.43M	377.00K	500.00K	0.00
	Gross Profit
-2.75B	-6.05M	-3.24M	-85.00K	0.00
	EBIT
-46.05B	-48.48M	-56.17M	-27.42M	-8.28M
	EBITDA
-46.05B	-49.75M	-54.23M	-27.41M	482.00
	Net Income Common Stockholders
-45.53M	-52.67M	-56.17M	-28.74M	-8.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
22.36B	18.90M	22.47M	53.66M	111.25K
	Total Assets
30.71B	27.27M	32.51M	59.00M	2.19M
	Total Debt
21.25B	15.26M	2.00M	0.00	0.00
	Net Debt
-1.10B	-3.64M	-20.48M	-53.66M	-111.25K
	Total Liabilities
25.32B	29.58M	9.46M	4.26M	15.71M
	Stockholders Equity
5.39B	-2.31M	23.05M	54.74M	-13.52M
Cash Flow		Free Cash Flow
-44.14B	-33.04M	-30.59M	-18.53M	-5.63M
	Operating Cash Flow
-44.14B	-32.82M	-29.68M	-17.67M	-5.63M
	Investing Cash Flow
-646.00M	-221.00K	-4.11M	-862.00K	0.00
	Financing Cash Flow
48.25B	29.46M	2.61M	72.08M	5.58M

Lucid Diagnostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.28
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LUCD, the sentiment is Positive. The current price of 1.28 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.40, and above the 200-day MA of 0.99, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 46.62 is Neutral, neither overbought nor oversold. The STOCH value of 23.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LUCD.

Lucid Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LUCD	60 Neutral	$134.83M	―	-2956.43%	―	79.00%	15.03%
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
NKTR	48 Neutral	$123.57M	―	-124.10%	―	9.22%	60.01%
LXEO	38 Underperform	$113.53M	―	-85.37%	―	―	-24.18%
BIOA	33 Underperform	$150.57M	―	36.83%	―	―	―

Lucid Diagnostics Corporate Events

Lucid Diagnostics Closes $16.1 Million Public Offering

On April 11, 2025, Lucid Diagnostics Inc. announced the closing of its public offering of 14,375,000 shares of common stock at $1.20 per share, raising approximately $16.1 million in net proceeds. The funds will be used for working capital and general corporate purposes, with Canaccord Genuity LLC and Maxim Group LLC managing the offering. This move is expected to bolster Lucid’s financial position as it continues to focus on cancer prevention diagnostics.

Spark’s Take on LUCD Stock

According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.

Lucid Diagnostics is experiencing rapid revenue growth but faces substantial financial instability due to negative margins and cash flows. The positive technical trend and favorable earnings call outlook provide some optimism. However, the negative valuation metrics reflect ongoing challenges. Recent financing efforts strengthen the balance sheet, yet reliance on debt remains a concern.

To see Spark’s full report on LUCD stock, click here.

Lucid Diagnostics Announces Public Stock Offering

On April 9, 2025, Lucid Diagnostics announced an underwritten public offering of its common stock, with Canaccord Genuity LLC as the sole bookrunner. The offering, priced at $1.20 per share, aims to raise approximately $15 million, with proceeds intended for working capital and general corporate purposes. The sale of 12,500,000 shares is expected to close around April 11, 2025, subject to customary closing conditions. The offering is made under an existing shelf registration statement, and the company has granted underwriters a 45-day option to purchase additional shares.

Spark’s Take on LUCD Stock

According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.

Lucid Diagnostics shows significant potential due to its strong revenue growth and recent strategic milestones, such as increased test volumes and insurance coverage. However, the company faces substantial financial challenges, including profitability issues and negative cash flows. Technical indicators suggest positive momentum, but the company’s negative P/E ratio and lack of dividends highlight ongoing financial and operational risks.

To see Spark’s full report on LUCD stock, click here.

Lucid Diagnostics Raises $15.3 Million in Stock Offering

On March 5, 2025, Lucid Diagnostics Inc. announced the closing of its registered direct offering, raising approximately $15.3 million through the sale of 13,939,331 shares of common stock at $1.10 per share. The net proceeds, estimated at $14.5 million after expenses, will be used for working capital and general corporate purposes, potentially strengthening the company’s financial position and supporting its operations in the cancer prevention diagnostics industry.

Lucid Diagnostics Announces $15.3 Million Direct Offering

On March 4, 2025, Lucid Diagnostics announced a $15.3 million registered direct offering by entering into subscription agreements with accredited investors to sell shares of common stock. The proceeds will be used for working capital and general corporate purposes, with Canaccord Genuity acting as the sole placement agent. This move is expected to bolster Lucid’s financial position and support its operations in the cancer prevention diagnostics industry.